Clinical Trial Update: Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes [Phase 4]

View source ↗

Summary

A Phase 4 Bayer study in postmenopausal women evaluates the lowest effective dose to relieve moderate-to-severe hot flashes, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Snippet

Sponsor: Bayer | Conditions: Hot Flashes | Phase 4 | Status: COMPLETED